HRT Financial’s Kairos Pharma KAPA Stock Holding History

HRT Financial’s Portfolio KAPA Stock Details KAPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,082	Closed	-$12K	–	5608
2026 Q1	$12K	Buy	3,082 +36	+1%	+$169	﹤0.01%	3622
2025 Q4	$15K	Buy	+3,046	New	+$20K	﹤0.01%	3020
2025 Q3	–	Sell	-1,891	Closed	-$9K	–	3858
2025 Q2	$9K	Buy	+1,891	New	+$9.63K	﹤0.01%	2460
2024 Q4	–	Sell	-1,801	Closed	-$19K	–	3426
2024 Q3	$19K	Buy	+1,801	New	+$25.8K	﹤0.01%	2194

Other funds holding KAPA

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SFG

SevenBridge Financial Group Harrisburg, Pennsylvania $680M AUM 30.75% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial's KAPA Position: Q2 2026 in Review

HRT Financial sold out of Kairos Pharma (KAPA) in Q2 2026, closing a stake of 3,082 shares — an estimated $12K sold.

HRT Financial first reported a position in KAPA in Q3 2024 and held it in 4 quarters. The position peaked at $19K in Q3 2024. 14 funds tracked by Wall St. Rank hold KAPA as of Q2 2026.

HRT Financial reported no remaining Kairos Pharma position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 3,082 Kairos Pharma shares in Q2 2026, an estimated $12K.
HRT Financial first reported a position in Kairos Pharma in Q3 2024 and held it in 4 quarters.
HRT Financial's Kairos Pharma position peaked at $19K in Q3 2024.
14 funds tracked by Wall St. Rank held Kairos Pharma as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.